Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue with fludarabine: Effect on tumor microenvironment

Leukemia and Lymphoma

Volumn 52, Issue 12, 2011, Pages 2262-2269

  De Boer, Jan Paul ^a   Raderer, Markus ^b   Van Tinteren, Harm ^a   Aleman, Berthe M P ^a   Boot, Henk ^a   De Jong, Daphne ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Extranodal marginal zone lymphoma; Fludarabine; FOXP3; Tregs

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; FLUDARABINE; OMEPRAZOLE; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; FLOW CYTOMETRY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; LYMPHOCYTIC INFILTRATION; MALE; MONOTHERAPY; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; STOMACH BIOPSY; TUMOR MICROENVIRONMENT;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; NEOPLASM STAGING; T-LYMPHOCYTE SUBSETS; TUMOR MICROENVIRONMENT; VIDARABINE;

EID: 82255196107     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.607527     Document Type: Article

References (48)

1. Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 1983;52:1410-1416. (Pubitemid 13017202)
2. Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat Rev Cancer 2004;4:644-653. (Pubitemid 39025059)
3. Cavalli F, Isaacson PG, Gascoyne RD, et al. MALT Lymphomas. Hematology Am Soc Hematol Educ Program 2001:241-258.
4. Bertoni F, Zucca E. State-of-the-art therapeutics: marginal-zone lymphoma. J Clin Oncol 2005;23:6415-6420. (Pubitemid 46218852)
5. Roggero E, Zucca E, Pinotti G, et al. Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med 1995;122:767-769.
6. Hussell T, Isaacson PG, Spencer J. Proliferation and dif erentiation of tumour cells from B-cell lymphoma of mucosa-associated lymphoid tissue in vitro. J Pathol 1993;169:221-227. (Pubitemid 23063460)
7. Isaacson PG. Gastric MALT lymphoma: from concept to cure. Ann Oncol 1999;10:637-645. (Pubitemid 29342367)
8. Tsang R, Gospodarowicz M, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003;21:4157-4164. (Pubitemid 46606184)
9. Hammel P, Haioun C, Chaumette MT, et al. Ef cacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol 1995;13:2524-2529.
10. Conconi A, Martinelli G, Tieblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003;102:2741-2745. (Pubitemid 37248842)
11. Jager G, Neumeister P, Brezinschek R, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol 2002;20:3872-3877.
12. Salar A, Domingo-Domenech E, Estany C, et al. Combination therapy with rituximab and intravenous or oral f udarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer 2009;115:5210-5217.
13. Fabbri A, Lenoci M, Gozzetti A, et al. Low-dose oral f udarabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma. Br J Haematol 2007;139:90-93. (Pubitemid 47389921)
14. Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classif cation of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.
15. Liu H, Ye H, Ruskone-Fourmestraux A, et al. t(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 2002;122:1286-1294. (Pubitemid 34465171)
16. Zinzani PL, Stefoni V, Musuraca G, et al. Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. Cancer 2004;100:2190-2194. (Pubitemid 38580339)
17. Czuczman MS, Koryzna A, Mohr A, et al. Rituximab in combination with f udarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005;23:694-704. (Pubitemid 46224168)
18. Robak T, Jamroziak K, Gora-Tybor J, et al. Comparison of cladribine plus cyclophosphamide with f udarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 study). J Clin Oncol 2010;28:1863-1869.
19. Copie-Bergman C, Gaulard P, Lavergne-Slove A, et al. Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma. Gut 2003;52:1656. (Pubitemid 37363454)
20. Glas AM, Knoops L, Delahaye L, et al. Gene-expression and immunohistochemical study of specif c T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007;25:390-398. (Pubitemid 350002987)
21. Suarez F, Lortholary O, Hermine O, et al. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood 2006;107:3034-3044.
22. Hussell T, Isaacson PG, Crabtree JE, et al. Te response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet 1993;342:571-574. (Pubitemid 23259232)
23. Hussell T, Isaacson PG, Crabtree JE, et al. Helicobacter pylori-specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. J Pathol 1996;178: 122-127.
24. Bayerdorfer E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet 1995;345:1591-1594.
25. Savio A, Franzin G, Wotherspoon AC, et al. Diagnosis and posttreatment follow-up of Helicobacter pylori-positive gastric lymphoma of mucosa-associated lymphoid tissue: histology, polymerase chain reaction, or both? Blood 1996;87:1255-1260. (Pubitemid 26056888)
26. Montalban C, Manzanal A, Boixeda D, et al. Helicobacter pylori eradication for the treatment of low-grade gastric MALT lymphoma: follow-up together with sequential molecular studies. Ann Oncol 1997;8(Suppl. 2):37-39.
27. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 2001;357:39-40. (Pubitemid 32056501)
28. Bastie JN, Cazals-Hatem D, Daniel MT, et al. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4 + lymphocytopenia after treatment. Leuk Lymphoma 1999;35: 555-565. (Pubitemid 30015655)
29. O'Brien S, Kantarjian H, Beran M, et al. Results of f udarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment see comments. Blood 1993;82:1695-1700. (Pubitemid 23278758)
30. Jager G, Neumeister P, Quehenberger F, et al. Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6 year follow-up of a phase II trial. Ann Oncol 2006;17: 1722-1723. (Pubitemid 44680898)
31. Ruskone-Fourmestraux A, Fischbach W, Aleman BM, et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 2011;50:747-758.
32. Levy M, Copie-Bergman C, Molinier-Frenkel V, et al. Treatment of t(11;18)-positive gastric mucosa-associated lymphoid tissue lymphoma with rituximab and chlorambucil: clinical, histological, and molecular follow-up. Leuk Lymphoma 2009;51:284-290.
33. Brown J, Friedberg J, Feng Y, et al. A phase 2 study of concurrent f udarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol 2009;145:741-748.
34. Peinert S, Carney D, Prince HM, et al. Fludarabine combinations for patients with advanced marginal zone lymphomas-best treatment option or too toxic? Br J Haematol 2009;146:685-686.
35. Carney DA, Westerman DA, Tam CS, et al. T erapy-related myelodysplastic syndrome and acute myeloid leukemia following f udarabine combination chemotherapy. Leukemia 2010;24:2056-2062.
36. Armitage JO, Carbone PP, Connors JM, et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003;21:897-906. (Pubitemid 46613489)
37. Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4 + CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with f udarabine. Blood 2005;106:2018-2025. (Pubitemid 41291715)
38. de Jong D, Fest T. Te microenvironment in follicular lymphoma. Best Pract Res Clin Hematol 2011;24:135-146.
39. Steidl C, Connors J, Gascoyne R. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 2011;29:1812-1826.
40. Farinha P, Al Tourah A, Gill K, et al. Te architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood 2010;115:289-295.
41. Knoops L, Haas R, de Kemp S, et al. In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma. Blood 2007;110:1116-1122. (Pubitemid 47281406)
42. D'Elios MM, Amedei A, Manghetti M, et al. Impaired T-cell regulation of B-cell growth in Helicobacter pylori-related gastric low-grade MALT lymphoma. Gastroenterology 1999;117:1105-1112. (Pubitemid 29512669)
43. Kindlund B, Sjoling A, Hansson M, et al. FOXP3-expressing CD4(+) T-cell numbers increase in areas of duodenal gastric metaplasia and are associated to CD4(+) T-cell aggregates in the duodenum of Helicobacter pylori-infected duodenal ulcer patients. Helicobacter 2009;14:192-201.
44. Raghavan S, Fredriksson M, Svennerholm AM, et al. Absence of CD4 + CD25 + regulatory T cells is associated with a loss of regulation leading to increased pathology in Helicobacter pylori-infected mice. Clin Exp Immunol 2003;132:393-400. (Pubitemid 36713944)
45. Lundgren A, Suri-Payer E, Enarsson K, et al. Helicobacter pylori-specif c CD4 + CD25high regulatory T cells suppress memory T-cell responses to H. pylori in infected individuals. Infect Immun 2003;71:1755-1762. (Pubitemid 36368704)
46. Craig VJ, Cogliatti SB, Arnold I, et al. B-cell receptor signaling and CD40 ligand-independent T cell help cooperate in Helicobacter-induced MALT lymphomagenesis. Leukemia 2010;24:1186-1196
47. Musshof K. Clinical staging classif cation of non-Hodgkin's lymphomas (author's transl). Strahlentherapie 1977;153:218-221. In German.
48. Radaszkiewicz T, Dragosics B, Bauer P. Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis. Gastroenterology 1992;102:1628-1638.